CN111467341A - 3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用 - Google Patents
3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用 Download PDFInfo
- Publication number
- CN111467341A CN111467341A CN202010333553.4A CN202010333553A CN111467341A CN 111467341 A CN111467341 A CN 111467341A CN 202010333553 A CN202010333553 A CN 202010333553A CN 111467341 A CN111467341 A CN 111467341A
- Authority
- CN
- China
- Prior art keywords
- drug
- tumor
- pharmaceutical composition
- resistant
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 39
- 206010059866 Drug resistance Diseases 0.000 title claims abstract description 27
- 239000012313 reversal agent Substances 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 42
- 229940079593 drug Drugs 0.000 claims abstract description 38
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- 229960001156 mitoxantrone Drugs 0.000 claims description 12
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 5
- 229940034982 antineoplastic agent Drugs 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 229940009456 adriamycin Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003435 antirheumatic agent Substances 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000006201 parenteral dosage form Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000006208 topical dosage form Substances 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 14
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 12
- 125000005605 benzo group Chemical group 0.000 abstract description 12
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 abstract description 11
- 238000011160 research Methods 0.000 abstract description 11
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 108010078791 Carrier Proteins Proteins 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000002441 reversible effect Effects 0.000 abstract description 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 229940124301 concurrent medication Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 10
- 230000036457 multidrug resistance Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 3
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 3
- 239000003560 cancer drug Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010333553.4A CN111467341B (zh) | 2020-04-24 | 2020-04-24 | 3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010333553.4A CN111467341B (zh) | 2020-04-24 | 2020-04-24 | 3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111467341A true CN111467341A (zh) | 2020-07-31 |
CN111467341B CN111467341B (zh) | 2021-05-11 |
Family
ID=71764082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010333553.4A Active CN111467341B (zh) | 2020-04-24 | 2020-04-24 | 3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111467341B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112402425A (zh) * | 2020-11-26 | 2021-02-26 | 山东师范大学 | 3,5-二硝基苯基-吡唑并[3,4-d][1,3]恶嗪作为肿瘤耐药逆转剂的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646504A (zh) * | 2001-12-05 | 2005-07-27 | 惠氏公司 | 作为雌激素药物的取代苯并噁唑和类似物 |
CN101137626A (zh) * | 2005-03-08 | 2008-03-05 | 惠氏公司 | 2-(3-氟-4-羟基苯基)-7-乙烯基-1,3-苯并唑-5-醇的晶形及其作为雌激素受体调节剂的用途 |
-
2020
- 2020-04-24 CN CN202010333553.4A patent/CN111467341B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646504A (zh) * | 2001-12-05 | 2005-07-27 | 惠氏公司 | 作为雌激素药物的取代苯并噁唑和类似物 |
CN101137626A (zh) * | 2005-03-08 | 2008-03-05 | 惠氏公司 | 2-(3-氟-4-羟基苯基)-7-乙烯基-1,3-苯并唑-5-醇的晶形及其作为雌激素受体调节剂的用途 |
Non-Patent Citations (1)
Title |
---|
姜亚丽: "《STN-CAS:175881-00-2》", 31 December 1996 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112402425A (zh) * | 2020-11-26 | 2021-02-26 | 山东师范大学 | 3,5-二硝基苯基-吡唑并[3,4-d][1,3]恶嗪作为肿瘤耐药逆转剂的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111467341B (zh) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102255753B1 (ko) | 뮤신 관련 질환의 치료 | |
JP7183371B2 (ja) | 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット | |
CN112386596B (zh) | 一种抗肿瘤联合用药物组合物及其应用 | |
KR20160106042A (ko) | 암 치료용 약학적 배합물 | |
CN111467341B (zh) | 3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用 | |
CN111388477B (zh) | 2-苯基吡唑[1,5-a]嘧啶类化合物作为肿瘤耐药逆转剂的应用 | |
WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
CN113637045A (zh) | 原人参二醇衍生物及其制备方法和应用 | |
US20100279964A1 (en) | Angular Pyranocoumarins, Process for Preparation and Uses Thereof | |
WO2007132220A1 (en) | Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder | |
WO2007132221A1 (en) | Combined anticancer pyrimidine-thiazole aurora kinase inhibitors | |
CN112402425B (zh) | 3,5-二硝基苯基-吡唑并[3,4-d][1,3]恶嗪作为肿瘤耐药逆转剂的应用 | |
CN111388463B (zh) | 朝藿素c或组合物在制备治疗肺癌制剂中的应用 | |
CN110590778B (zh) | 3,10二对甲氧基苯基6,12二氮杂四高立方烷类化合物及合成方法和药物组合物 | |
KR20140035974A (ko) | 종양 질환 치료를 위한 약제 조성물 | |
CN110343070B (zh) | 一种微管蛋白抑制剂及其制备方法与应用 | |
CN110893192B (zh) | 治疗鼻咽癌的药物组合物 | |
CN107501219B (zh) | 不对称姜黄色素类化合物及其在制备抗胃癌药物中的应用 | |
JP2002526540A (ja) | 細胞毒性アルカロイド類(ハリツリン) | |
WO2022198777A1 (zh) | 一种三氮唑类化合物在制备抗肿瘤药物中的应用 | |
CN101157628B (zh) | 一类取代苯甲酸类含氮衍生物及其抗肿瘤医药用途 | |
CN111297870B (zh) | 硝基苯甲酸类化合物在制备治疗肿瘤的药物中的应用 | |
CN110876800B (zh) | 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物 | |
WO2005099736A1 (ja) | 抗腫瘍治療薬 | |
CN116251107A (zh) | Z-2-366在用于制备抑制eEF2K表达的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230615 Address after: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi Xiangyuan Information Technology Co.,Ltd. Address before: 250014 No. 88, Wenhua East Road, Lixia District, Shandong, Ji'nan Patentee before: SHANDONG NORMAL University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240430 Address after: 201400 Building 1, No.1 Haikun Road, Fengxian District, Shanghai Patentee after: Shanghai Xianglihe Pharmaceutical Co.,Ltd. Country or region after: China Address before: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee before: Wuxi Xiangyuan Information Technology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |